By targeted bisulfite sequencing and RT‐qPCR, we further confirmed that DLX5 hypermethylation was a common event in myeloid neoplasms, and could see as a potential biological marker used in predicting disease prognosis in AML and MDS. Here, DLX5 is linked to myeloid neoplasm.